Search for: "Gottlieb v Gottlieb" Results 81 - 100 of 394
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
12 Jun 2019, 11:56 am by Jeff Margulies (US)
In a statement, FDA Commission Scott Gottlieb, M.D., stated: We’ve taken this position because we too have carefully reviewed the most current research on coffee and cancer and it does not support a cancer warning for coffee. [read post]
12 Jun 2019, 11:56 am by Jeff Margulies (US)
In a statement, FDA Commission Scott Gottlieb, M.D., stated: We’ve taken this position because we too have carefully reviewed the most current research on coffee and cancer and it does not support a cancer warning for coffee. [read post]
16 May 2019, 5:54 am
Posted by Jennifer Kennedy Park, Lev Dassin, and Georgia Stasinopoulos, Cleary Gottlieb Steen & Hamilton LLP, on Thursday, May 16, 2019 Editor's Note: Jennifer Kennedy Park and Lev Dassin are partners and Georgia V. [read post]
15 May 2019, 9:06 pm by Edward Hale
The agency, however, has reclassified FDA-Approved drugs that contain less than 0.1 percent CBD as Schedule V drugs—an apparent carve out for Epidolex. [read post]
14 May 2019, 4:25 am by Andrew Lavoott Bluestone
Fine Art Ltd. v Lacher, 115 AD3d 600, 601 (1st Dept 2014) (finding that “[p]laintiffs’ claims of excessive billing and related conduct, which actions [were] not alleged to have adversely affected their claims or defenses in the underlying action, [did] not state a claim for legal malpractice”); see also Gottlieb, Rackman & Reisman, P. [read post]
19 Apr 2019, 6:12 am
Rouhandeh, and Michael Kaplan, Davis Polk & Wardwell LLP, on Saturday, April 13, 2019 Tags: Bonds, Corporate fraud, DOJ, International governance, Misconduct, Rule 144, SEC, SEC enforcement, Securities litigation, Securities regulation, Volkswagen 2019 Proposed Amendments to DGCL Posted by John Mark Zeberkiewicz and Brigitte Fresco, Richards, Layton & Finger, P.A., on Saturday, April 13, 2019 Tags: Appraisal… [read post]
12 Apr 2019, 6:20 am
Securities and Exchange Commission, on Wednesday, April 10, 2019 Tags: Accountability, No-action letters, Public interest, SEC, Securities regulation, Transparency Executive Long-Term Incentive Plans Posted by Joseph Kieffer, Equilar Inc., on Thursday, April 11, 2019 Tags: Compensation ratios, Equity-based compensation, Executive Compensation, Incentives, Management, Pay for performance The SEC v. [read post]
5 Apr 2019, 5:58 am
Pruitt, Jones Day, on Tuesday, April 2, 2019 Tags: Broker-dealers, Conflicts of interest, Disclosure, Investment advisers, Investor protection, Mutual funds, Reporting regulation, Retail investors, SEC, SEC enforcement FCPA and the Commodity Exchange Act: A New Relationship Posted by David Yeres, David DiBari, and Robert Houck, Clifford Chance US LLP, on Tuesday, April 2, 2019 Tags: Anti-corruption, CFTC, Commodity… [read post]